Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization tastatic breast cancer treated with trastuzumab

Cancer

Volumn 116, Issue 22, 2010, Pages 5168-5178

  Lipton, Allan ^a   Köstler, Wolfgang J ^b   Leitzel, Kim ^a   Ali, Suhail M ^a,c   Sperinde, Jeff ^d   Weidler, Jodi ^e   Paquet, Agnes ^e   Sherwood, Thomas ^e   Huang, Weidong ^e   Bates, Michael ^e  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Monogram Biosciences   (United States)

^e Division of Clinical Research   (United States)

Author keywords

erbB2; fluorescence in situ hybridization; HER2 neu; HERmark; immunohistochemistry; metastatic breast cancer; predictive biomarker; trastuzumab; VeraTag

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; COHORT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 78449281431     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25430     Document Type: Article

References (24)

1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17: 2639-2648.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719-726.
6. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-137.
7. Slamon DJ,. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest. 1990; 8: 253.
8. Slamon DJ, Clark GM,. Amplification of c-erbB-2 and aggressive human breast tumors? Science. 1988; 240: 1795-1798.
9. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
10. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712.
11. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005; 23: 4287-4297.
12. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651-3664.
13. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006; 24: 3032-3038.
14. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005; 11: 6598-6607.
15. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002; 20: 3095-3105.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
17. Paik S, Kim C, Wolmark N,. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008; 358: 1409-1411.
18. Tuma RS,. Inconsistency of HER2 test raises questions. J Natl Cancer Inst. 2007; 99: 1064-1065.
19. Singer C, Kostler W, Hudelist G,. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta. 2008; 1786: 105-113.
20. Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10: 1618-1624.
21. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Natl Cancer Inst. 2005; 97: 1180-1184.
22. Shi Y, Huang W, Tan Y, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009; 18: 11-21.
23. Larson J, Goodman L, Tan Y, et al. Analytical validation of a highly quantitative, sensitive, accurate, and reproducible assay (HERmark) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens. Pathol Res Int. In press.
24. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. In press.